Methods for diagnosing benign prostatic hyperplasia

Details Methods for diagnosing benign prostatic hyperplasia Methods for diagnosing benign prostatic hyperplasia

1995-02-23

1997-12-16

Bahr, Jennifer

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

128898, 435 794, 436 64, 436 86, G01N 33573, G01N 33574, G01N 3368

Patent

active

056984022

ABSTRACT:
The present invention relates to a method for diagnosing benign prostatic hyperplasia (BPH) in a male human patient without requiring a biopsy. The total prostate specific antigen (PSA) level in the blood or serum of the patient is measured. If the patient has a total PSA level of between 2.5 ng/ml, (4.0 ng/ml for those 60 years or over), and 10.0 ng/ml, then the free PSA level in the blood or serum of the patient is measured. The proportion of free PSA to total PSA is calculated. If this proportion is equal to or greater than about 25%, then the patient is diagnosed as having BPH.

REFERENCES:
patent: 5501983 (1996-03-01), Lilja et al.
Oesterling et al. Influence of Patient Age on the Serum PSA Concentration. Urologic Clinics of North America. vol. 20, No. 4, pp. 671-680, Nov. 1993.
A. Christensson et al. Serum Prostate Specific Antigen Complexed to 1-Antichymotrypsin as an Indicator of Prostate Cancer, The Journal of Urology, vol. 150 pp. 100-105, Jul. 1993.

Affiliated with

Also associated with

Rating

Methods for diagnosing benign prostatic hyperplasia does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for diagnosing benign prostatic hyperplasia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for diagnosing benign prostatic hyperplasia will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-204664